



Demonstrated statistically significant results with median PFS on combination of encorafenib plus binimetinib 14.9 months versus 7.3 months on vemurafenib

Generally well-tolerated and safety profile overall consistent with prior encorafenib plus binimetinib clinical trial results

C

Global regulatory submissions planned for 2017

Boulder, Colo., Castres, France (September 26, 2016) - Array BioPharma (Nasdaq: ARRY) and Pierre Fabre today jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS (Co mbined L GX818

Écrit par Pierre Fabre - Array BioPharma

Mardi, 27 Septembre 2016 10:04 - Mis à jour Mardi, 27 Septembre 2016 10:08

U
sed with
M
EK162 in
B
RAF
Mutant
U
nresectable
S
kin Cancer
)
study evaluating
LGX818 (encorafenib)
, a BRAF inhibitor,
and MEK162 (binimetinib)
, a MEK inhibitor,
in patients with
BRAF
-mutant advanced, unresectable or metastatic
melanoma
. The study met its primary endpoint, significantly improving progression free survival
(PFS)
compared with
vemurafenib
, a BRAF inhibitor
, alone
.

"The COLUMBUS Part 1 trial results demonstrate a robust PFS benefit associated with the combination of binimetinib plus encorafenib versus vemurafenib in patients with BRAF -mutant melanoma," said Ron Squarer, Chief Executive Officer, Array BioPharma. "We look forward to working with

Array BioPharma and Pierre Fabre Announce COLUMBUS Phase 3 Study of Encorafenib plus Binimetinib

Écrit par Pierre Fabre - Array BioPharma

Mardi, 27 Septembre 2016 10:04 - Mis à jour Mardi, 27 Septembre 2016 10:08

global regulatory authorities
as they evaluate
our planned submission
."

In the analysis of the primary endpoint, the median PFS for patients treated with the combination of encorafenib plus binimetinib ("combination") was 14.9 months versus 7.3 months for patients treated with vemurafenib; HR (0.54) [95% CI 0.41-0.71], p